Search

Your search keyword '"Kulbe, Hagen"' showing total 274 results
Start Over Author "Kulbe, Hagen"
274 results on '"Kulbe, Hagen"'

1. Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer

Author

Arends, Christopher Maximilian, Kopp, Klara, Hablesreiter, Raphael, Estrada, Natalia, Christen, Friederike, Moll, Ute Martha, Zeillinger, Robert, Schmitt, Wolfgang Daniel, Sehouli, Jalid, Kulbe, Hagen, Fleischmann, Maximilian, Ray-Coquard, Isabelle, Zeimet, Alain, Raspagliesi, Francesco, Zamagni, Claudio, Vergote, Ignace, Lorusso, Domenica, Concin, Nicole, Bullinger, Lars, Braicu, Elena Ioana, and Damm, Frederik

Published
2024
Full Text
View/download PDF

2. AHRR and SFRP2 in primary versus recurrent high-grade serous ovarian carcinoma and their prognostic implication

Author

Monjé, Nanna, Dragomir, Mihnea P., Sinn, Bruno V., Hoffmann, Inga, Makhmut, Anuar, Simon, Tincy, Kunze, Catarina A., Ihlow, Jana, Schmitt, Wolfgang D., Pohl, Jonathan, Piwonski, Iris, Marchenko, Sofya, Keunecke, Carlotta, Calina, Teodor G., Tiso, Francesca, Kulbe, Hagen, Kreuzinger, Caroline, Cacsire Castillo-Tong, Dan, Sehouli, Jalid, Braicu, Elena I., Denkert, Carsten, Darb-Esfahani, Silvia, Kübler, Kirsten, Capper, David, Coscia, Fabian, Morkel, Markus, Horst, David, Sers, Christine, and Taube, Eliane T.

Published
2024
Full Text
View/download PDF

3. Correction: Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer

Author

Arends, Christopher Maximilian, Kopp, Klara, Hablesreiter, Raphael, Estrada, Natalia, Christen, Friederike, Moll, Ute Martha, Zeillinger, Robert, Schmitt, Wolfgang Daniel, Sehouli, Jalid, Kulbe, Hagen, Fleischmann, Maximilian, Ray-Coquard, Isabelle, Zeimet, Alain, Raspagliesi, Francesco, Zamagni, Claudio, Vergote, Ignace, Lorusso, Domenica, Concin, Nicole, Bullinger, Lars, Braicu, Elena Ioana, and Damm, Frederik

Published
2024
Full Text
View/download PDF

4. High EVI1 and PARP1 expression as favourable prognostic markers in high-grade serous ovarian carcinoma

Author

Jank, Paul, Leichsenring, Jonas, Kolb, Svenja, Hoffmann, Inga, Bischoff, Philip, Kunze, Catarina Alisa, Dragomir, Mihnea P., Gleitsmann, Moritz, Jesinghaus, Moritz, Schmitt, Wolfgang D., Kulbe, Hagen, Sers, Christine, Stenzinger, Albrecht, Sehouli, Jalid, Braicu, Ioana Elena, Westhoff, Christina, Horst, David, Denkert, Carsten, Gröschel, Stefan, and Taube, Eliane T.

Published
2023
Full Text
View/download PDF

6. Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium

Author

Glajzer, Jacek, Castillo-Tong, Dan Cacsire, Richter, Rolf, Vergote, Ignace, Kulbe, Hagen, Vanderstichele, Adriaan, Ruscito, Ilary, Trillsch, Fabian, Mustea, Alexander, Kreuzinger, Caroline, Gourley, Charlie, Gabra, Hani, Taube, Eliane T., Dorigo, Oliver, Horst, David, Keunecke, Carlotta, Baum, Joanna, Angelotti, Timothy, Sehouli, Jalid, and Braicu, Elena Ioana

Published
2023
Full Text
View/download PDF

7. LRP1B—a prognostic marker in tubo-ovarian high-grade serous carcinoma

Author

Kolb, Svenja, Hoffmann, Inga, Monjé, Nanna, Dragomir, Mihnea P., Jank, Paul, Bischoff, Philip, Keunecke, Carlotta, Pohl, Jonathan, Kunze, Catarina Alisa, Marchenko, Sofya, Schmitt, Wolfgang D., Kulbe, Hagen, Sers, Christine, Sehouli, Jalid, Braicu, Elena Ioana, Denkert, Carsten, Darb-Esfahani, Silvia, Horst, David, Sinn, Bruno V., and Taube, Eliane T.

Published
2023
Full Text
View/download PDF

8. Increased expression of IDO1 is associated with improved survival and increased number of TILs in patients with high-grade serous ovarian cancer

Author

Hoffmann, Inga, Dragomir, Mihnea P., Monjé, Nanna, Keunecke, Carlotta, Kunze, Catarina Alisa, Schallenberg, Simon, Marchenko, Sofya, Schmitt, Wolfgang D., Kulbe, Hagen, Sehouli, Jalid, Braicu, Ioana Elena, Jank, Paul, Denkert, Carsten, Darb-Esfahani, Silvia, Horst, David, Sinn, Bruno V., Sers, Christine, Bischoff, Philip, and Taube, Eliane T.

Published
2023
Full Text
View/download PDF

9. ASO Visual Abstract: Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome, and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer (HGSOC). A Multicenter, Retrospective Study of the Ovarian Cancer Therapy—Innovative Models Prolong Survival (OCTIPS) Consortium

Author

Glajzer, Jacek, Castillo-Tong, Dan Cacsire, Richter, Rolf, Vergote, Ignace, Kulbe, Hagen, Vanderstichele, Adriaan, Ruscito, Ilary, Trillsch, Fabian, Mustea, Alexander, Kreuzinger, Caroline, Gourley, Charlie, Gabra, Hani, Taube, Eliane T., Dorigo, Oliver, Horst, David, Keunecke, Carlotta, Baum, Joanna, Angelotti, Timothy, Sehouli, Jalid, and Braicu, Elena Ioana

Published
2023
Full Text
View/download PDF

14. Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer

Author

Stanske, Mandy, Wienert, Stephan, Castillo-Tong, Dan Cacsire, Kreuzinger, Caroline, Vergote, Ignace, Lambrechts, Sandrijne, Gabra, Hani, Gourley, Charlie, Ganapathi, Ram N., Kolaschinski, Ivonne, Budczies, Jan, Sehouli, Jalid, Ruscito, Ilary, Denkert, Carsten, Kulbe, Hagen, Schmitt, Wolfgang, Jöhrens, Korinna, Braicu, Ioana, and Darb-Esfahani, Silvia

Published
2018
Full Text
View/download PDF

15. Vascular endothelial growth factor receptor 2 (VEGFR2) correlates with long-term survival in patients with advanced high-grade serous ovarian cancer (HGSOC): a study from the Tumor Bank Ovarian Cancer (TOC) Consortium

Author

Guan, Jun, Darb-Esfahani, Silvia, Richter, Rolf, Taube, Eliane T., Ruscito, Ilary, Mahner, Sven, Woelber, Linn, Prieske, Katharina, Concin, Nicole, Vergote, Ignace, Van Nieuwenhuysen, Els, Achimas-Cadariu, Patriciu, Glajzer, Joanna, Woopen, Hannah, Stanske, Mandy, Kulbe, Hagen, Denkert, Carsten, Sehouli, Jalid, and Braicu, Elena Ioana

Published
2019
Full Text
View/download PDF

18. Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy–Innovative Models Prolong Survival (OCTIPS) Consortium

Author

Ruscito, Ilary, Cacsire Castillo-Tong, Dan, Vergote, Ignace, Ignat, Iulia, Stanske, Mandy, Vanderstichele, Adriaan, Ganapathi, Ram N., Glajzer, Jacek, Kulbe, Hagen, Trillsch, Fabian, Mustea, Alexander, Kreuzinger, Caroline, Benedetti Panici, Pierluigi, Gourley, Charlie, Gabra, Hani, Kessler, Mirjana, Sehouli, Jalid, Darb-Esfahani, Silvia, and Braicu, Elena Ioana

Published
2017
Full Text
View/download PDF

19. In Silico Analysis Predicts Nuclear Factors NR2F6 and YAP1 as Mesenchymal Subtype-Specific Therapeutic Targets for Ovarian Cancer Patients

Author

Kassuhn, Wanja, Rodriguez Cutillas, Pedro, Kessler, Mirjana, Sehouli, Jalid, Braicu, Elena I., Blüthgen, Nils, and Kulbe, Hagen

Subjects
molecular subtypes, ovarian cancer, therapeutics, ddc:610, tumour microenvironment, 610 Medizin und Gesundheit, cell–cell communication
Abstract

Background: Tumour heterogeneity in high-grade serous ovarian cancer (HGSOC) is a proposed cause of acquired resistance to treatment and high rates of relapse. Among the four distinct molecular subtypes of HGSOC, the mesenchymal subtype (MES) has been observed with high frequency in several study cohorts. Moreover, it exhibits aggressive characteristics with poor prognosis. The failure to adequately exploit such subtypes for treatment results in high mortality rates, highlighting the need for effective targeted therapeutic strategies that follow the idea of personalized medicine (PM). Methods: As a proof-of-concept, bulk and single-cell RNA data were used to characterize the distinct composition of the tumour microenvironment (TME), as well as the cell–cell communication and its effects on downstream transcription of MES. Moreover, transcription factor activity contextualized with causal inference analysis identified novel therapeutic targets with potential causal impact on transcription factor dysregulation promoting the malignant phenotype. Findings: Fibroblast and macrophage phenotypes are of utmost importance for the complex intercellular crosstalk of MES. Specifically, tumour-associated macrophages were identified as the source of interleukin 1 beta (IL1B), a signalling molecule with significant impact on downstream transcription in tumour cells. Likewise, signalling molecules tumour necrosis factor (TNF), transforming growth factor beta (TGFB1), and C-X-C motif chemokine 12 (CXCL12) were prominent drivers of downstream gene expression associated with multiple cancer hallmarks. Furthermore, several consistently hyperactivated transcription factors were identified as potential sources for treatment opportunities. Finally, causal inference analysis identified Yes-associated protein 1 (YAP1) and Nuclear Receptor Subfamily 2 Group F Member 6 (NR2F6) as novel therapeutic targets in MES, verified in an independent dataset. Interpretation: By utilizing a sophisticated bioinformatics approach, several candidates for treatment opportunities, including YAP1 and NR2F6 were identified. These candidates represent signalling regulators within the cellular network of the MES. Hence, further studies to confirm these candidates as potential targeted therapies in PM are warranted. Deutsche Krebshilfe

Published
2023
Full Text
View/download PDF

20. Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study).

Author

Ruscito, Ilary, Cacsire Castillo-Tong, Dan, Vergote, Ignace, Ignat, Iulia, Stanske, Mandy, Vanderstichele, Adriaan, Glajzer, Jacek, Kulbe, Hagen, Trillsch, Fabian, Mustea, Alexander, Kreuzinger, Caroline, Benedetti Panici, Pierluigi, Gourley, Charlie, Gabra, Hani, Nuti, Marianna, Taube, Eliane T., Kessler, Mirjana, Sehouli, Jalid, Darb-Esfahani, Silvia, and Braicu, Elena Ioana

Published
2018
Full Text
View/download PDF

21. Supplementary Table S5 from IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer

Author

Anglesio, Michael S., primary, George, Joshy, primary, Kulbe, Hagen, primary, Friedlander, Michael, primary, Rischin, Danny, primary, Lemech, Charlotte, primary, Power, Jeremy, primary, Coward, Jermaine, primary, Cowin, Prue A., primary, House, Colin M., primary, Chakravarty, Probir, primary, Gorringe, Kylie L., primary, Campbell, Ian G., primary, Okamoto, Aikou, primary, Birrer, Michael J., primary, Huntsman, David G., primary, de Fazio, Anna, primary, Kalloger, Steve E., primary, Balkwill, Frances, primary, Gilks, C. Blake, primary, and Bowtell, David D., primary

Published
2023
Full Text
View/download PDF

23. Supplementary Tables 1-3 from Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer

Author

Coward, Jermaine, primary, Kulbe, Hagen, primary, Chakravarty, Probir, primary, Leader, David, primary, Vassileva, Vessela, primary, Leinster, D. Andrew, primary, Thompson, Richard, primary, Schioppa, Tiziana, primary, Nemeth, Jeffery, primary, Vermeulen, Jessica, primary, Singh, Naveena, primary, Avril, Norbert, primary, Cummings, Jeff, primary, Rexhepaj, Elton, primary, Jirström, Karin, primary, Gallagher, William M., primary, Brennan, Donal J., primary, McNeish, Iain A., primary, and Balkwill, Frances R., primary

Published
2023
Full Text
View/download PDF

24. Supplementary Figure 3 from Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer

Author

Coward, Jermaine, primary, Kulbe, Hagen, primary, Chakravarty, Probir, primary, Leader, David, primary, Vassileva, Vessela, primary, Leinster, D. Andrew, primary, Thompson, Richard, primary, Schioppa, Tiziana, primary, Nemeth, Jeffery, primary, Vermeulen, Jessica, primary, Singh, Naveena, primary, Avril, Norbert, primary, Cummings, Jeff, primary, Rexhepaj, Elton, primary, Jirström, Karin, primary, Gallagher, William M., primary, Brennan, Donal J., primary, McNeish, Iain A., primary, and Balkwill, Frances R., primary

Published
2023
Full Text
View/download PDF

25. Supplementary Figures S1-S5 from IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer

Author

Anglesio, Michael S., primary, George, Joshy, primary, Kulbe, Hagen, primary, Friedlander, Michael, primary, Rischin, Danny, primary, Lemech, Charlotte, primary, Power, Jeremy, primary, Coward, Jermaine, primary, Cowin, Prue A., primary, House, Colin M., primary, Chakravarty, Probir, primary, Gorringe, Kylie L., primary, Campbell, Ian G., primary, Okamoto, Aikou, primary, Birrer, Michael J., primary, Huntsman, David G., primary, de Fazio, Anna, primary, Kalloger, Steve E., primary, Balkwill, Frances, primary, Gilks, C. Blake, primary, and Bowtell, David D., primary

Published
2023
Full Text
View/download PDF

26. Supplementary Figure 1 from Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer

Author

Coward, Jermaine, primary, Kulbe, Hagen, primary, Chakravarty, Probir, primary, Leader, David, primary, Vassileva, Vessela, primary, Leinster, D. Andrew, primary, Thompson, Richard, primary, Schioppa, Tiziana, primary, Nemeth, Jeffery, primary, Vermeulen, Jessica, primary, Singh, Naveena, primary, Avril, Norbert, primary, Cummings, Jeff, primary, Rexhepaj, Elton, primary, Jirström, Karin, primary, Gallagher, William M., primary, Brennan, Donal J., primary, McNeish, Iain A., primary, and Balkwill, Frances R., primary

Published
2023
Full Text
View/download PDF

29. Supplementary Methods from IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer

Author

Anglesio, Michael S., primary, George, Joshy, primary, Kulbe, Hagen, primary, Friedlander, Michael, primary, Rischin, Danny, primary, Lemech, Charlotte, primary, Power, Jeremy, primary, Coward, Jermaine, primary, Cowin, Prue A., primary, House, Colin M., primary, Chakravarty, Probir, primary, Gorringe, Kylie L., primary, Campbell, Ian G., primary, Okamoto, Aikou, primary, Birrer, Michael J., primary, Huntsman, David G., primary, de Fazio, Anna, primary, Kalloger, Steve E., primary, Balkwill, Frances, primary, Gilks, C. Blake, primary, and Bowtell, David D., primary

Published
2023
Full Text
View/download PDF

30. Supplementary Figure 2 from Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer

Author

Coward, Jermaine, primary, Kulbe, Hagen, primary, Chakravarty, Probir, primary, Leader, David, primary, Vassileva, Vessela, primary, Leinster, D. Andrew, primary, Thompson, Richard, primary, Schioppa, Tiziana, primary, Nemeth, Jeffery, primary, Vermeulen, Jessica, primary, Singh, Naveena, primary, Avril, Norbert, primary, Cummings, Jeff, primary, Rexhepaj, Elton, primary, Jirström, Karin, primary, Gallagher, William M., primary, Brennan, Donal J., primary, McNeish, Iain A., primary, and Balkwill, Frances R., primary

Published
2023
Full Text
View/download PDF

31. Supplementary Table 4 from Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer

Author

Coward, Jermaine, primary, Kulbe, Hagen, primary, Chakravarty, Probir, primary, Leader, David, primary, Vassileva, Vessela, primary, Leinster, D. Andrew, primary, Thompson, Richard, primary, Schioppa, Tiziana, primary, Nemeth, Jeffery, primary, Vermeulen, Jessica, primary, Singh, Naveena, primary, Avril, Norbert, primary, Cummings, Jeff, primary, Rexhepaj, Elton, primary, Jirström, Karin, primary, Gallagher, William M., primary, Brennan, Donal J., primary, McNeish, Iain A., primary, and Balkwill, Frances R., primary

Published
2023
Full Text
View/download PDF

32. Supplementary Figure Legends 1-3 from Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer

Author

Coward, Jermaine, primary, Kulbe, Hagen, primary, Chakravarty, Probir, primary, Leader, David, primary, Vassileva, Vessela, primary, Leinster, D. Andrew, primary, Thompson, Richard, primary, Schioppa, Tiziana, primary, Nemeth, Jeffery, primary, Vermeulen, Jessica, primary, Singh, Naveena, primary, Avril, Norbert, primary, Cummings, Jeff, primary, Rexhepaj, Elton, primary, Jirström, Karin, primary, Gallagher, William M., primary, Brennan, Donal J., primary, McNeish, Iain A., primary, and Balkwill, Frances R., primary

Published
2023
Full Text
View/download PDF

33. Data from A Dynamic Inflammatory Cytokine Network in the Human Ovarian Cancer Microenvironment

Author

Kulbe, Hagen, primary, Chakravarty, Probir, primary, Leinster, D. Andrew, primary, Charles, Kellie A., primary, Kwong, Joseph, primary, Thompson, Richard G., primary, Coward, Jermaine I., primary, Schioppa, Tiziana, primary, Robinson, Stephen C., primary, Gallagher, William M., primary, Galletta, Laura, primary, Salako, Michael A., primary, Smyth, John F., primary, Hagemann, Thorsten, primary, Brennan, Donal J., primary, Bowtell, David D., primary, and Balkwill, Frances R., primary

Published
2023
Full Text
View/download PDF

34. Supplemental Figure Legends from Adaptive Upregulation of EGFR Limits Attenuation of Tumor Growth by Neutralizing IL6 Antibodies, with Implications for Combined Therapy in Ovarian Cancer

Author

Milagre, Carla S., primary, Gopinathan, Ganga, primary, Everitt, Gemma, primary, Thompson, Richard G., primary, Kulbe, Hagen, primary, Zhong, Haihong, primary, Hollingsworth, Robert E., primary, Grose, Richard, primary, Bowtell, David D.L., primary, Hochhauser, Daniel, primary, and Balkwill, Frances R., primary

Published
2023
Full Text
View/download PDF

35. Supplementary Figure 4 from Adaptive Upregulation of EGFR Limits Attenuation of Tumor Growth by Neutralizing IL6 Antibodies, with Implications for Combined Therapy in Ovarian Cancer

Author

Milagre, Carla S., primary, Gopinathan, Ganga, primary, Everitt, Gemma, primary, Thompson, Richard G., primary, Kulbe, Hagen, primary, Zhong, Haihong, primary, Hollingsworth, Robert E., primary, Grose, Richard, primary, Bowtell, David D.L., primary, Hochhauser, Daniel, primary, and Balkwill, Frances R., primary

Published
2023
Full Text
View/download PDF

36. Supplementary Figure 3 from Adaptive Upregulation of EGFR Limits Attenuation of Tumor Growth by Neutralizing IL6 Antibodies, with Implications for Combined Therapy in Ovarian Cancer

Author

Milagre, Carla S., primary, Gopinathan, Ganga, primary, Everitt, Gemma, primary, Thompson, Richard G., primary, Kulbe, Hagen, primary, Zhong, Haihong, primary, Hollingsworth, Robert E., primary, Grose, Richard, primary, Bowtell, David D.L., primary, Hochhauser, Daniel, primary, and Balkwill, Frances R., primary

Published
2023
Full Text
View/download PDF

37. Supplementary Table 2 from A Dynamic Inflammatory Cytokine Network in the Human Ovarian Cancer Microenvironment

Author

Kulbe, Hagen, primary, Chakravarty, Probir, primary, Leinster, D. Andrew, primary, Charles, Kellie A., primary, Kwong, Joseph, primary, Thompson, Richard G., primary, Coward, Jermaine I., primary, Schioppa, Tiziana, primary, Robinson, Stephen C., primary, Gallagher, William M., primary, Galletta, Laura, primary, Salako, Michael A., primary, Smyth, John F., primary, Hagemann, Thorsten, primary, Brennan, Donal J., primary, Bowtell, David D., primary, and Balkwill, Frances R., primary

Published
2023
Full Text
View/download PDF

38. Supplementary Figure Legends 1-4 from A Dynamic Inflammatory Cytokine Network in the Human Ovarian Cancer Microenvironment

Author

Kulbe, Hagen, primary, Chakravarty, Probir, primary, Leinster, D. Andrew, primary, Charles, Kellie A., primary, Kwong, Joseph, primary, Thompson, Richard G., primary, Coward, Jermaine I., primary, Schioppa, Tiziana, primary, Robinson, Stephen C., primary, Gallagher, William M., primary, Galletta, Laura, primary, Salako, Michael A., primary, Smyth, John F., primary, Hagemann, Thorsten, primary, Brennan, Donal J., primary, Bowtell, David D., primary, and Balkwill, Frances R., primary

Published
2023
Full Text
View/download PDF

39. Supplementary Figure 5 from Adaptive Upregulation of EGFR Limits Attenuation of Tumor Growth by Neutralizing IL6 Antibodies, with Implications for Combined Therapy in Ovarian Cancer

Author

Milagre, Carla S., primary, Gopinathan, Ganga, primary, Everitt, Gemma, primary, Thompson, Richard G., primary, Kulbe, Hagen, primary, Zhong, Haihong, primary, Hollingsworth, Robert E., primary, Grose, Richard, primary, Bowtell, David D.L., primary, Hochhauser, Daniel, primary, and Balkwill, Frances R., primary

Published
2023
Full Text
View/download PDF

40. Supplementary Figure 2 from Adaptive Upregulation of EGFR Limits Attenuation of Tumor Growth by Neutralizing IL6 Antibodies, with Implications for Combined Therapy in Ovarian Cancer

Author

Milagre, Carla S., primary, Gopinathan, Ganga, primary, Everitt, Gemma, primary, Thompson, Richard G., primary, Kulbe, Hagen, primary, Zhong, Haihong, primary, Hollingsworth, Robert E., primary, Grose, Richard, primary, Bowtell, David D.L., primary, Hochhauser, Daniel, primary, and Balkwill, Frances R., primary

Published
2023
Full Text
View/download PDF

41. Supplementary Figure 3 from A Dynamic Inflammatory Cytokine Network in the Human Ovarian Cancer Microenvironment

Author

Kulbe, Hagen, primary, Chakravarty, Probir, primary, Leinster, D. Andrew, primary, Charles, Kellie A., primary, Kwong, Joseph, primary, Thompson, Richard G., primary, Coward, Jermaine I., primary, Schioppa, Tiziana, primary, Robinson, Stephen C., primary, Gallagher, William M., primary, Galletta, Laura, primary, Salako, Michael A., primary, Smyth, John F., primary, Hagemann, Thorsten, primary, Brennan, Donal J., primary, Bowtell, David D., primary, and Balkwill, Frances R., primary

Published
2023
Full Text
View/download PDF

42. Supplementary Figure 1 from Adaptive Upregulation of EGFR Limits Attenuation of Tumor Growth by Neutralizing IL6 Antibodies, with Implications for Combined Therapy in Ovarian Cancer

Author

Milagre, Carla S., primary, Gopinathan, Ganga, primary, Everitt, Gemma, primary, Thompson, Richard G., primary, Kulbe, Hagen, primary, Zhong, Haihong, primary, Hollingsworth, Robert E., primary, Grose, Richard, primary, Bowtell, David D.L., primary, Hochhauser, Daniel, primary, and Balkwill, Frances R., primary

Published
2023
Full Text
View/download PDF

43. Supplementary Table 1 from A Dynamic Inflammatory Cytokine Network in the Human Ovarian Cancer Microenvironment

Author

Kulbe, Hagen, primary, Chakravarty, Probir, primary, Leinster, D. Andrew, primary, Charles, Kellie A., primary, Kwong, Joseph, primary, Thompson, Richard G., primary, Coward, Jermaine I., primary, Schioppa, Tiziana, primary, Robinson, Stephen C., primary, Gallagher, William M., primary, Galletta, Laura, primary, Salako, Michael A., primary, Smyth, John F., primary, Hagemann, Thorsten, primary, Brennan, Donal J., primary, Bowtell, David D., primary, and Balkwill, Frances R., primary

Published
2023
Full Text
View/download PDF

44. Supplementary Figure 4 from A Dynamic Inflammatory Cytokine Network in the Human Ovarian Cancer Microenvironment

Author

Kulbe, Hagen, primary, Chakravarty, Probir, primary, Leinster, D. Andrew, primary, Charles, Kellie A., primary, Kwong, Joseph, primary, Thompson, Richard G., primary, Coward, Jermaine I., primary, Schioppa, Tiziana, primary, Robinson, Stephen C., primary, Gallagher, William M., primary, Galletta, Laura, primary, Salako, Michael A., primary, Smyth, John F., primary, Hagemann, Thorsten, primary, Brennan, Donal J., primary, Bowtell, David D., primary, and Balkwill, Frances R., primary

Published
2023
Full Text
View/download PDF

45. Data from Adaptive Upregulation of EGFR Limits Attenuation of Tumor Growth by Neutralizing IL6 Antibodies, with Implications for Combined Therapy in Ovarian Cancer

Author

Milagre, Carla S., primary, Gopinathan, Ganga, primary, Everitt, Gemma, primary, Thompson, Richard G., primary, Kulbe, Hagen, primary, Zhong, Haihong, primary, Hollingsworth, Robert E., primary, Grose, Richard, primary, Bowtell, David D.L., primary, Hochhauser, Daniel, primary, and Balkwill, Frances R., primary

Published
2023
Full Text
View/download PDF

46. Supplementary Figure 2 from A Dynamic Inflammatory Cytokine Network in the Human Ovarian Cancer Microenvironment

Author

Kulbe, Hagen, primary, Chakravarty, Probir, primary, Leinster, D. Andrew, primary, Charles, Kellie A., primary, Kwong, Joseph, primary, Thompson, Richard G., primary, Coward, Jermaine I., primary, Schioppa, Tiziana, primary, Robinson, Stephen C., primary, Gallagher, William M., primary, Galletta, Laura, primary, Salako, Michael A., primary, Smyth, John F., primary, Hagemann, Thorsten, primary, Brennan, Donal J., primary, Bowtell, David D., primary, and Balkwill, Frances R., primary

Published
2023
Full Text
View/download PDF

47. Supplementary Figure 1 from A Dynamic Inflammatory Cytokine Network in the Human Ovarian Cancer Microenvironment

Author

Kulbe, Hagen, primary, Chakravarty, Probir, primary, Leinster, D. Andrew, primary, Charles, Kellie A., primary, Kwong, Joseph, primary, Thompson, Richard G., primary, Coward, Jermaine I., primary, Schioppa, Tiziana, primary, Robinson, Stephen C., primary, Gallagher, William M., primary, Galletta, Laura, primary, Salako, Michael A., primary, Smyth, John F., primary, Hagemann, Thorsten, primary, Brennan, Donal J., primary, Bowtell, David D., primary, and Balkwill, Frances R., primary

Published
2023
Full Text
View/download PDF

48. ASO Visual Abstract: Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome, and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer (HGSOC). A Multicenter, Retrospective Study of the Ovarian Cancer Therapy—Innovative Models Prolong Survival (OCTIPS) Consortium

Author

Glajzer, Jacek, primary, Castillo-Tong, Dan Cacsire, additional, Richter, Rolf, additional, Vergote, Ignace, additional, Kulbe, Hagen, additional, Vanderstichele, Adriaan, additional, Ruscito, Ilary, additional, Trillsch, Fabian, additional, Mustea, Alexander, additional, Kreuzinger, Caroline, additional, Gourley, Charlie, additional, Gabra, Hani, additional, Taube, Eliane T., additional, Dorigo, Oliver, additional, Horst, David, additional, Keunecke, Carlotta, additional, Baum, Joanna, additional, Angelotti, Timothy, additional, Sehouli, Jalid, additional, and Braicu, Elena Ioana, additional

Published
2022
Full Text
View/download PDF

49. A CCR4 antagonist reverses the tumor-promoting microenvironment of renal cancer

Author

Berlato, Chiara, Khan, Moddasar N., Schioppa, Tiziana, Thompson, Richard, Maniati, Eleni, Montfort, Anne, Jangani, Maryam, Canosa, Monica, Kulbe, Hagen, Hagemann, Urs B., Duncan, Alexander R., Fletcher, Laura, Wilkinson, Robert W., Powles, Thomas, Quezada, Sergio A., and Balkwill, Frances R.

Subjects
Antagonists (Biochemistry) -- Research, Renal cell carcinoma -- Research -- Genetic aspects, Gene expression -- Research, Health care industry
Abstract

Elevated expression of the chemokine receptor CCR4 in tumors is associated with poor prognosis in several cancers. Here, we have determined that CCR4 was highly expressed in human renal cell carcinoma (RCC) biopsies and observed abnormal levels of CCR4 ligands in RCC patient plasma. An antagonistic anti-CCR4 antibody had antitumor activity in the RENCA mouse model of RCC. CCR4 inhibition did not reduce the proportion of infiltrating leukocytes in the tumor microenvironment but altered the phenotype of myeloid cells, increased NK cell and Th1 cytokine levels, and reduced immature myeloid cell infiltrate and blood chemokine levels. In spite of prominent changes in the myeloid compartment, the anti-CCR4 antibody did not affect RENCA tumors in T cell-deficient mice, and treatment with an anti- class II MHC antibody abrogated its antitumor activity. We concluded that the effects of the anti-CCR4 antibody required the adaptive immune system and [CD4.sup.+] T cells. Moreover, CCL17-induced IFN-[gamma] production was reduced when Th1-polarized normal [CD4.sup.+] T cells were exposed to the CCR4 ligand, evidencing the involvement of CCR4 in Th1/Th2 regulation. The anti-CCR4 antibody, alone or in combination with other immune modulators, is a potential treatment approach to human solid cancers with high levels of CCR4-expressing tumor-infiltrating leukocytes and abnormal plasma CCR4 ligand levels., Introduction Tumor microenvironments possess complex chemokine networks that contribute to the extent and phenotype of the host infiltrate (1-3). In addition, malignant cells may gain functional chemokine receptors, often as [...]

Published
2017
Full Text
View/download PDF

50. Low Expression of RGS2 Promotes Poor Prognosis in High-Grade Serous Ovarian Cancer

Author

Ihlow, Jana, primary, Monjé, Nanna, additional, Hoffmann, Inga, additional, Bischoff, Philip, additional, Sinn, Bruno Valentin, additional, Schmitt, Wolfgang Daniel, additional, Kunze, Catarina Alisa, additional, Darb-Esfahani, Sylvia, additional, Kulbe, Hagen, additional, Braicu, Elena Ioana, additional, Sehouli, Jalid, additional, Denkert, Carsten, additional, Horst, David, additional, and Taube, Eliane Tabea, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results